Price History
Investment Checklist
Technical Analysis
Technical Analysis
Analysis from 2026-06-12
Trend
Price below most MAs — downtrend | Bearish MA stack (20<50<200)
Price Action
Support & Resistance Levels
Volume Analysis
Recent MA Crossovers
Stop Loss Levels
Fixed Risk
Technical Levels
Financials
Financial Analysis
| Metric | Mar '25 | Jun '25 | Sep '25 | Dec '25 |
|---|---|---|---|---|
| Revenue | ₹100.9 Cr | ₹87.9 Cr | ₹75 Cr | ₹94.5 Cr |
| Net Profit | ₹11.9 Cr | ₹12.7 Cr | ₹10.6 Cr | ₹12.4 Cr |
| EPS | — | ₹2.54 | ₹2.11 | ₹2.49 |
| Operating Profit | ₹20.8 Cr | ₹21 Cr | ₹18.4 Cr | ₹19.4 Cr |
Peer Comparison
Specialty ChemicalsPeer Comparison
| Symbol | Name | Price | Change |
|---|---|---|---|
| PIDILITIND | Pidilite Industries Limited | ₹1,535.50 | +2.45% |
| SRF | SRF Limited | ₹2,743.00 | +3.18% |
| FLUOROCHEM | Gujarat Fluorochemicals Limited | ₹3,655.30 | -0.68% |
| NAVINFLUOR | Navin Fluorine International Limited | ₹7,303.00 | +2.04% |
| DEEPAKNTR | Deepak Nitrite Limited | ₹1,669.90 | +3.57% |
| ATUL | Atul Limited | ₹6,517.50 | +0.32% |
| AARTIIND | Aarti Industries Limited | ₹440.60 | +2.98% |
| AETHER | Aether Industries Limited | ₹1,142.90 | +1.25% |
| BASF | BASF India Limited | ₹3,356.50 | +3.21% |
| FINEORG | Fine Organic Industries Limited | ₹4,724.70 | +1.02% |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 14 Nov 2025 | Interim Dividend - Re 1.50 Per Share | INTERIM_DIVIDEND |
| 17 Sept 2025 | Dividend - Rs 1.50 Per Share | DIVIDEND |
| 01 Aug 2025 | Interim Dividend - Rs 1.50 Per Share | INTERIM_DIVIDEND |
| 24 Jan 2025 | Interim Dividend - Rs 1.50 Per Share | INTERIM_DIVIDEND |
| 19 Nov 2024 | Interim Dividend - Re 1 Per Share | INTERIM_DIVIDEND |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for VIDHIING
View AllVenus Remedies gets Saudi FDA approval for speciality oncology therapy
Venus Remedies Limited has secured its first global marketing authorization for its specialty oncology therapy, Plerixafor, from the Saudi Food and Drug Authority (SFDA). This hematopoietic stem cell mobilizer is crucial for patients undergoing stem cell transplantation for multiple myeloma and non-Hodgkin lymphoma.
Venus Remedies receives Saudi FDA approval for Plerixafor
Venus Remedies has received Marketing Authorization from the Saudi Food and Drug Authority (SFDA) for Plerixafor. This is the first Marketing Authorization Venus Remedies has secured for Plerixafor anywhere in the world. It is also a deliberate step in the company's move toward complex, higher-value specialty injectables in oncology and critical care, replacing reliance on commodity injectable volumes with diifferentiated therapies in regulated markets.
Vidhi Specialty Food Ingredients consolidated net profit rises 10.50% in the March 2026 quarter
Sales rise 12.01% to Rs 122.68 crore
